AU2021275327A1 - Exosome-derived PIWI-interacting RNA and methods of use thereof - Google Patents

Exosome-derived PIWI-interacting RNA and methods of use thereof Download PDF

Info

Publication number
AU2021275327A1
AU2021275327A1 AU2021275327A AU2021275327A AU2021275327A1 AU 2021275327 A1 AU2021275327 A1 AU 2021275327A1 AU 2021275327 A AU2021275327 A AU 2021275327A AU 2021275327 A AU2021275327 A AU 2021275327A AU 2021275327 A1 AU2021275327 A1 AU 2021275327A1
Authority
AU
Australia
Prior art keywords
pir
pirna
derived
hsa
exosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021275327A
Other languages
English (en)
Inventor
Alessandra CIULLO
Ahmed G. IBRAHIM
Eduardo MARBÁN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2021275327A1 publication Critical patent/AU2021275327A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021275327A 2020-05-19 2021-05-17 Exosome-derived PIWI-interacting RNA and methods of use thereof Pending AU2021275327A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027191P 2020-05-19 2020-05-19
US63/027,191 2020-05-19
PCT/US2021/070568 WO2021237238A1 (en) 2020-05-19 2021-05-17 Exosome-derived piwi-interacting rna and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2021275327A1 true AU2021275327A1 (en) 2022-12-08

Family

ID=78707679

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021275327A Pending AU2021275327A1 (en) 2020-05-19 2021-05-17 Exosome-derived PIWI-interacting RNA and methods of use thereof

Country Status (6)

Country Link
US (1) US20230203487A1 (https=)
EP (1) EP4153743A4 (https=)
JP (1) JP2023527766A (https=)
CN (1) CN115698286A (https=)
AU (1) AU2021275327A1 (https=)
WO (1) WO2021237238A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
CN116875682B (zh) * 2023-07-08 2024-06-11 中国人民解放军总医院第二医学中心 用于诊断急性心肌梗死心脏损伤的piRNA标志物、试剂盒及其应用
WO2026035943A1 (en) 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids
CN120485350B (zh) * 2025-04-12 2026-04-10 中国人民解放军总医院第二医学中心 用于诊断评估脓毒症心肌病的piRNA标志物、试剂盒及其应用
CN120713928A (zh) * 2025-06-30 2025-09-30 山西农业大学 miR-126及携带miR-126的外泌体在促进骨骼肌损伤修复和增殖分化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3083997T (pt) * 2013-12-20 2020-11-03 Univ Lausanne Utilizações diagnósticas, prognósticas e terapêuticas de rnas longos não codificadores para doenças cardíacas e medicina regenerativa
CN104548136B (zh) * 2015-01-27 2018-02-13 青岛大学 一种piRNA药物组合物及其用途
WO2017147594A1 (en) * 2016-02-26 2017-08-31 Yale University COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
HUE048369T2 (hu) * 2017-07-17 2020-07-28 Univ Masarykova Diagnosztikai eljárás végbélrák kimutatására
US11667916B2 (en) * 2017-09-08 2023-06-06 Korea University Research And Business Foundation Composition for preventing or treating liver fibrosis, containing exosome or exosome-derived ribonucleic acid
EP3749344A4 (en) * 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS

Also Published As

Publication number Publication date
US20230203487A1 (en) 2023-06-29
WO2021237238A1 (en) 2021-11-25
CN115698286A (zh) 2023-02-03
EP4153743A4 (en) 2025-09-24
JP2023527766A (ja) 2023-06-30
EP4153743A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
US20230203487A1 (en) Exosome-derived piwi-interacting rna and methods of use thereof
Wang et al. Targeted therapy for inflammatory diseases with mesenchymal stem cells and their derived exosomes: from basic to clinics
US12584127B2 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
AU2017219054B2 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP3200808B1 (en) Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
ES3054848T3 (en) Stem cell-derived exosomes for the treatment of corneal scarring
Huang et al. Macrophage membrane-camouflaged biomimetic nanovesicles for targeted treatment of arthritis
CN101072866A (zh) 通过施用rna改变细胞性质的方法
JP2020534344A (ja) 表皮水疱症を処置するための方法及び組成物
Chae et al. Exosome-based therapy in cardiovascular diseases: a new frontier in cardiovascular disease treatment
Park et al. A nonbiodegradable scaffold-free cell sheet of genome-engineered mesenchymal stem cells inhibits development of acute kidney injury
CN113795261A (zh) 针对纤维化、炎症、及/或衰老症的治疗药
US20240123034A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
US20240216532A1 (en) Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia
US20240374649A1 (en) Method for Treating Ilk Signaling Pathway Related Diseases Using Exosome Derived from Mesenchymal Stem Cells, and Pharmaceutical Composition
Yuka et al. Current Approaches in Cardiac Repair: Somatic and Stem Cell Exosomes
US20230414673A1 (en) Extracellular vesicles derived from cardiosphere-derived cells as anti-shock therapeutics
CN120037408A (zh) 药物组合物及其在制备治疗肝脏疾病的药物中的应用
CN115887679A (zh) 一种基因-化疗纳米药物共递送系统、其制备方法和用途
CN115558635A (zh) 一种大鼠心梗组织提取液、外泌体及其应用
HK40120941A (en) Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
AU2006207381A1 (en) Method of treatment by administration of RNA
CN119770672A (zh) 一种心脏靶向的纳米脂质体递送载体、治疗心血管疾病的环状rna药物及其制备方法和应用
Carbone et al. Placenta-Derived Stem Cells as a Source for Treatment of Lung and Liver Disease in Cystic Fibrosis
Kjems et al. Extracellular vesicular miRNAs in osteoblastogenesis